Comparison of the Effects of a 12-Week Consumption of Two Carbonated Beverages on Insulin Sensitivity (SEDULC)

The purpose of this study is to determine whether consumption of carbonated drinks containing sweeteners affect insulin sensitivity.

Study Overview

Detailed Description

Sweeteners are natural or synthetic sugar substitutes which provide a sweetness taste to drink and food with few or no additional calories. Sweeteners are widely used in commercialized beverages. Despite some debate, no significant toxicity was demonstrated at a reasonable level of consumption (less than 20 cans per day). However little data is available on the metabolic effects of a regular consumption of beverages containing sweeteners. The objective of the study is to evaluate the effect of a regular consumption (twice a day for 12 weeks) of a carbonated drink with sweeteners, in a normal diet, compared with unsweetened sparkling water on insulin sensitivity in healthy normoweight and overweight subjects.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rennes, France, 35033 Rennes Cedex 9
        • Unit of Clinical Investigation,Centre Hospitalo-Universitaire de Rennes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy male or female
  • Subject taking at least three main meals (breakfast, lunch, dinner)
  • Subject able to understand and sign an informed consent
  • Subject drinking and enjoying soft drinks
  • Subject appreciating sweeteners taste
  • 19 kg/m² < BMI< 30 kg/m²

Exclusion Criteria:

  • Any severe or acute illness that may influence the results of the study or may be life-threatening
  • Pregnant or breastfeeding subject
  • Past or present metabolic or digestive diseases, with the exception of a possible appendectomy
  • Diabetes or severe acute illness that may alter blood sugar
  • Treatment that may interfere with glucose homeostasis
  • Past or present kidney disease (renal failure, ... )
  • Local or systemic medication that may change water status, metabolism and feeding behavior
  • Antiplatelet treatment
  • Alcohol consumption ≥ 3-4 glasses / day ( ≥ 21 drinks / week )
  • Sustained physical exercise (more than 4 hours per week)
  • Subject adding sweeteners (tablets or powder) in their diet
  • Subject drinking more than two cans of drinks with sweeteners / day
  • Subject dieting to lose weight
  • Subject unable or unwilling to consume 2 liters of fluid / day

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Drink with sweeteners
Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Active Comparator: Drink without sweeteners
Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Matsuda Insulin sensitivity Index
Time Frame: Before and after each of the two 12-week intervention period
Before and after each of the two 12-week intervention period

Secondary Outcome Measures

Outcome Measure
Time Frame
Insulinogenic Index defined as ∆ insulin 0-30 / ∆ glucose 0-30
Time Frame: Before and after each of the two 12-week intervention period
Before and after each of the two 12-week intervention period
Disposition index defined as Insulin sensitivity x insulinogenic Index
Time Frame: Before and after each of the two 12-week intervention period
Before and after each of the two 12-week intervention period
HOMA-IR Index defined as fasting Glycemia x fasting insulinemia/22.5
Time Frame: Before and after each of the two 12-week intervention period
Before and after each of the two 12-week intervention period
Dietary intake
Time Frame: Before and after each of the two 12-week intervention period
Before and after each of the two 12-week intervention period
Physical activity
Time Frame: Before and after each of the two 12-week intervention period
Before and after each of the two 12-week intervention period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Fabrice Bonnet, MD, PhD, Centre Hospitalo-Universitaire de Rennes
  • Study Director: Fabrice Lainé, MD, PhD, Centre Hospitalo-Universitaire de Rennes

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

April 1, 2014

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

January 8, 2014

First Submitted That Met QC Criteria

January 8, 2014

First Posted (Estimate)

January 9, 2014

Study Record Updates

Last Update Posted (Actual)

March 3, 2017

Last Update Submitted That Met QC Criteria

March 2, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 2012EL0905SEDULC
  • 120901-10 (Other Identifier: ANSM)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glucose Homeostasis

Clinical Trials on Drink with sweeteners

3
Subscribe